AstraZeneca

Activities: Drug Delivery Research & Development Pharmaceutical

Trending Articles

  1. Olon strengthens market position with acquisitions ahead of CPHI Milan Two new acquisitions expand Olon’s service offerings and production capacity
  2. Improving the sustainability of pharmaceutical freeze drying with ECO Mode Freeze dryers are typically associated with high levels of energy consumption; to counteract this issue, GEA Pharma & Healthcare has introduced the LYOVAC ECO Mode, which...
  3. Microbial identification of drug contamination: MALDI-TOF MS as an efficient alternative This article describes the growing need for fast and accurate microbial detection in the pharmaceutical manufacturing supply chain
  4. Almac Group announces £11m investment to expand global analytical services The Almac Group has announced an £11m investment and the creation of more than 100 new jobs to expand its global analytical services capabilities
  5. Neopac unveils new Polyfoil mono-material barrier mini tubes Small-size tubes enhance protection and versatility for pharmaceutical and oral care applications

Upcoming event

ISCC

15-18 October 2024 | Conference | Milan, Italy See all

Related Content

Regulatory

AstraZeneca's Tagrisso obtains FDA approval for use in stage III NSCLC

Tagrisso reduced the risk of disease progression or death by 84% compared to placebo in the Phase III LAURA trial
Design & Build

AstraZeneca opens a 'people hub' at its Macclesfield site

The energy-efficient building will offer AZ employees a collaborative space
Regulatory

AstraZeneca's Fasenra for severe eosinophilic asthma approved in China

The NMPA approval stems from the results of the MIRACLE Phase III trial, which found a 74% reduction in the annualised asthma exacerbation rate
Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Regulatory

AstraZeneca & Daiichi Sankyo's Enhertu bags another approval for gastric cancer applications

The HER2-targeting ADC has received conditional approval owing to the results of the DESTINY-Gastric06 Phase II trial
Finance

AstraZeneca completes acquisition of Amolyt Pharma

The $1.05bn acquisition has been completed, and will bolster AstraZeneca's rare endocrine disease pipeline
Regulatory

Tagrisso plus chemo for advanced lung cancer approved in the EU

Tagrisso and chemotherapy improved progression-free survival by 38% when compared with monotherapy alone
Subscribe now